RS62136B1 - Kristalne tozilatne soli selektivnog inhibitora pi3k delta za upotrebu u farmaceutskim formulacijama - Google Patents

Kristalne tozilatne soli selektivnog inhibitora pi3k delta za upotrebu u farmaceutskim formulacijama

Info

Publication number
RS62136B1
RS62136B1 RS20210920A RSP20210920A RS62136B1 RS 62136 B1 RS62136 B1 RS 62136B1 RS 20210920 A RS20210920 A RS 20210920A RS P20210920 A RSP20210920 A RS P20210920A RS 62136 B1 RS62136 B1 RS 62136B1
Authority
RS
Serbia
Prior art keywords
disease
cancer
tgr
salt
ptsa salt
Prior art date
Application number
RS20210920A
Other languages
English (en)
Serbian (sr)
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of RS62136B1 publication Critical patent/RS62136B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20210920A 2014-05-27 2015-05-26 Kristalne tozilatne soli selektivnog inhibitora pi3k delta za upotrebu u farmaceutskim formulacijama RS62136B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations
EP15733532.4A EP3149000B1 (en) 2014-05-27 2015-05-26 Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
RS62136B1 true RS62136B1 (sr) 2021-08-31

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210920A RS62136B1 (sr) 2014-05-27 2015-05-26 Kristalne tozilatne soli selektivnog inhibitora pi3k delta za upotrebu u farmaceutskim formulacijama

Country Status (22)

Country Link
US (4) US9969740B2 (enExample)
EP (2) EP3149000B1 (enExample)
JP (3) JP6987501B2 (enExample)
KR (1) KR20170007480A (enExample)
CN (2) CN111635406A (enExample)
AU (1) AU2015265542B2 (enExample)
BR (1) BR112016027674A2 (enExample)
CA (1) CA2949932C (enExample)
CY (1) CY1124316T1 (enExample)
DK (1) DK3149000T3 (enExample)
EA (1) EA032506B1 (enExample)
ES (1) ES2880999T3 (enExample)
HR (1) HRP20211151T1 (enExample)
HU (1) HUE054916T2 (enExample)
IL (1) IL249058B2 (enExample)
LT (1) LT3149000T (enExample)
PL (1) PL3149000T3 (enExample)
PT (1) PT3149000T (enExample)
RS (1) RS62136B1 (enExample)
SI (1) SI3149000T1 (enExample)
SM (1) SMT202100532T1 (enExample)
WO (1) WO2015181728A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211151T1 (hr) * 2014-05-27 2021-10-15 Rhizen Pharmaceuticals S.A. Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
WO2018049263A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
JP2022540466A (ja) * 2019-07-15 2022-09-15 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 非晶質ウムブラリシブモノトシレート
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2567260T3 (es) * 2000-04-25 2016-04-21 Icos Corporation Inhibidores de la fosfatidilinositol 3-quinasa delta humana
RS20100366A (sr) 2002-12-16 2011-04-30 Genentech, Inc. Varijante imunoglobulina i njihova upotreba
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
AU2013285081B2 (en) * 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
HRP20211151T1 (hr) * 2014-05-27 2021-10-15 Rhizen Pharmaceuticals S.A. Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama

Also Published As

Publication number Publication date
HRP20211151T1 (hr) 2021-10-15
AU2015265542A1 (en) 2016-12-08
US9969740B2 (en) 2018-05-15
EP3149000B1 (en) 2021-06-30
JP2020122022A (ja) 2020-08-13
HUE054916T2 (hu) 2021-10-28
US10414773B2 (en) 2019-09-17
PT3149000T (pt) 2021-07-27
SMT202100532T1 (it) 2021-11-12
US20170121336A1 (en) 2017-05-04
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
ES2880999T3 (es) 2021-11-26
EP3149000A1 (en) 2017-04-05
DK3149000T3 (da) 2021-08-30
EA201692255A1 (ru) 2017-04-28
KR20170007480A (ko) 2017-01-18
EP3971188A1 (en) 2022-03-23
AU2015265542B2 (en) 2019-05-09
LT3149000T (lt) 2021-09-10
CN111635406A (zh) 2020-09-08
IL249058B (en) 2022-11-01
CN106661030A (zh) 2017-05-10
JP2017516785A (ja) 2017-06-22
CA2949932C (en) 2021-08-10
WO2015181728A1 (en) 2015-12-03
IL249058B2 (en) 2023-03-01
US20190016725A1 (en) 2019-01-17
CA2949932A1 (en) 2015-12-03
JP2022082680A (ja) 2022-06-02
US20190382411A1 (en) 2019-12-19
BR112016027674A2 (pt) 2017-08-15
JP6987501B2 (ja) 2022-01-05
CY1124316T1 (el) 2022-07-22
US10947244B2 (en) 2021-03-16
PL3149000T3 (pl) 2021-11-02
SI3149000T1 (sl) 2021-09-30
IL249058A0 (en) 2017-01-31
US20210269446A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US10947244B2 (en) Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
AU2017227929B2 (en) Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase
MX2013007278A (es) Compuestos de quinolina sustituidos y metodos de uso.
AU2022216284A9 (en) Combination therapy for treating abnormal cell growth
JP2024533423A (ja) 薬学的組成物およびその使用
CN112839656A (zh) 急性骨髓性白血病用抗肿瘤剂
CN117377492A (zh) 包含蛋白激酶抑制剂的药物组合物及其医药用途
CA3189235A1 (en) Dosage form compositions comprising an inhibitor of btk and mutants thereof
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
EP3195865A1 (de) Kombinationen von irak4 inhibitoren und btk inhibitoren
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
TW201924719A (zh) 抑制腫瘤移轉的方法
KR20200055117A (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
CN100494177C (zh) 具有抗肿瘤活性的双酰胺基杂环类衍生物及其制备方法和用途
HK40046231A (en) Antitumor agent for acute myeloid leukemia
HK40042521B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
HK40033357A (en) Methods of inhibiting tumor metastasis